Scilex Holding Co. Files 8-K on Stock and Warrants
Ticker: SCLXW · Form: 8-K · Filed: Dec 10, 2024 · CIK: 1820190
| Field | Detail |
|---|---|
| Company | Scilex Holding Co (SCLXW) |
| Form Type | 8-K |
| Filed Date | Dec 10, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: stock-details, warrants, regulatory-filing
Related Tickers: SCLX
TL;DR
Scilex 8-K: Common stock par value $0.00001, warrants exercise price $1.150.
AI Summary
Scilex Holding Company filed an 8-K on December 10, 2024, reporting on its common stock and warrants. The filing details the par value of its common stock as $0.00001 per share and the exercise price of its warrants to purchase one share of common stock at $1.150 per share. This filing is a routine update regarding the company's capital structure.
Why It Matters
This filing provides clarity on the terms of Scilex's outstanding common stock and warrants, which is important for investors to understand their rights and potential dilution.
Risk Assessment
Risk Level: low — This is a routine regulatory filing providing basic information about the company's capital structure and does not indicate any new material events or risks.
Key Numbers
- $0.00001 — Common Stock Par Value (Represents the nominal value per share of Scilex's common stock.)
- $1.150 — Warrant Exercise Price (The price at which holders can exercise their warrants to purchase one share of common stock.)
Key Players & Entities
- Scilex Holding Co (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- 001-39852 (file_number) — SEC File Number
- 92-1062542 (tax_id) — IRS Employer Identification No.
- $0.00001 (dollar_amount) — Par value of common stock
- $1.150 (dollar_amount) — Exercise price of warrants
FAQ
What is the par value of Scilex Holding Company's common stock?
The par value of Scilex Holding Company's common stock is $0.00001 per share.
What is the exercise price for Scilex Holding Company's warrants?
The exercise price for Scilex Holding Company's warrants to purchase one share of common stock is $1.150 per share.
On what date was this 8-K filing reported?
This 8-K filing was reported on December 10, 2024.
In which state is Scilex Holding Company incorporated?
Scilex Holding Company is incorporated in Delaware.
What is the SEC file number for Scilex Holding Company?
The SEC file number for Scilex Holding Company is 001-39852.
Filing Stats: 632 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2024-12-10 08:15:19
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share SCLX The Nasdaq Stock Mar
- $11.50 — mon stock, each at an exercise price of $11.50 per share SCLXW The Nasdaq Stock Ma
Filing Documents
- sclx-20241210.htm (8-K) — 44KB
- sclx-ex99_1.htm (EX-99.1) — 46KB
- sclx-ex99_2.htm (EX-99.2) — 42KB
- img191798281_0.jpg (GRAPHIC) — 14KB
- img191798281_1.jpg (GRAPHIC) — 8KB
- img191798281_2.jpg (GRAPHIC) — 11KB
- img191798281_3.jpg (GRAPHIC) — 17KB
- img192721802_0.jpg (GRAPHIC) — 14KB
- img192721802_1.jpg (GRAPHIC) — 8KB
- img192721802_2.jpg (GRAPHIC) — 11KB
- img192721802_3.jpg (GRAPHIC) — 17KB
- 0000950170-24-134767.txt ( ) — 449KB
- sclx-20241210.xsd (EX-101.SCH) — 59KB
- sclx-20241210_htm.xml (XML) — 6KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On December 10, 2024, Scilex Holding Company (the "Company") issued press releases announcing the signing of (i) a binding term sheet with IPMC Company ("IPMC"), the representative company of the Bio Open Innovation Consortium, to create a joint venture arrangement (the "JV") involving the formation of a new entity for the sole purpose of globally developing and commercializing a potential novel oral central nervous system ("CNS") compound, KDS2010, a Phase 2, novel oral tablet for the treatment of obesity and neurodegenerative diseases, including Alzheimer's disease; and (ii) a binding term sheet with NeuroBiogen Company ("NB"), pursuant to which NB will grant the JV worldwide rights, with rights to sublicense, for all indications of KDS2010. Copies of the press releases are furnished herewith as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibits 99.1 and 99.2 attached hereto is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, dated December 10, 2024. 99.2 Press Release, dated December 10, 2024. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SCILEX HOLDING COMPANY By: /s/ Jaisim Shah Name: Jaisim Shah Date: December 10, 2024 Title: Chief Executive Officer and President 3